Testing Tobacco Products Promoted to Reduce Harm (R21)

The summary for the Testing Tobacco Products Promoted to Reduce Harm (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Testing Tobacco Products Promoted to Reduce Harm (R21)
	CFDA Number:	93.279
	CFDA Description:	Drug Abuse and Addiction Research Programs
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-09-047
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Feb 19, 2009
	Creation Date:	Feb 19, 2009
	Original Closing Date for Applications:	May 07, 2012
	Current Closing Date for Applications:	May 07, 2012
	Archive Date:	Jun 07, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.
Grant Description: Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI) and the National Institute on Drug Abuse (NIDA), invites applications that propose multidisciplinary research on potential reduced-exposure tobacco products, both smoked and smokeless. The multidisciplinary studies can span basic, biological, behavioral, surveillance, and epidemiology research. The tobacco industry is currently promoting several new products with claims that they: a) are less either harmful or less addictive; and b) purportedly deliver lower amounts of toxic, carcinogenic, and/or addictive agents to the user compared with conventional products. However, to date, the scientific evidence is insufficient to evaluate whether these new products actually reduce the users exposure or risk for tobacco-related diseases. The overarching goal of this FOA is to determine whether potential reduced-exposure tobacco products provide a truly, less-harmful alternative to conventional tobacco products, both at the individual and population level. Mechanism of Support. This FOA utilizes the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-046, which uses the NIH Research Project Grant (R01) mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. Research Plan Component Length: Items 2-5 of the PHS398 Research Plan component of the R21 application may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts. For information on NIH Exploratory/Developmental Research Grant Award (R21). Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply. Eligible Project Directors/Principal Investigators (PDs/PIs). Include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application. Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct. Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement).See new NIH policy on resubmission (amended) applications (NOT-OD-09-003, NOT-OD-09-016).
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-09-047.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1); • Pre-Application for the FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (X02); • Pre-Application for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the...; • 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance ...; • International Tobacco and Health Research and Capacity Building Program (R01); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • DRUG ABUSE ASPECTS OF HIV/AIDS AND OTHER INFECTIONS; • EPIDEMIOLOGY OF DRUG ABUSE; • PRESCRIPTION DRUG ABUSE; • MDMA: RESEARCH AREAS NEEDING MORE EMPHASIS